Clinuvel Pharmaceuticals Limited (ASX:CUV)

Clinuvel Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Operating Revenue	94.02	95.02	81.22	72.18	60
Other Revenue	-	-	6.96	6.14	5.72
Revenue	94.02	95.02	88.18	78.32	65.72
Revenue Growth	-1.04%	7.76%	12.58%	19.17%	36.02%
Cost of Revenue	15.81	14.81	7.73	7.52	9.25
Gross Profit	78.21	80.2	80.45	70.8	56.47
Selling, General & Admin	19.59	18.23	22.84	15.65	13.03
Research & Development	18.09	20.7	2.35	1.27	1.23
Other Operating Expenses	-	-	-0.56	-0.02	-0.22
Operating Expenses	37.68	38.93	31.88	26.67	20.92
Operating Income	40.53	41.27	48.57	44.13	35.55
Interest Expense	-	-	-4.45	-3.19	-2.27
Interest & Investment Income	10.45	9.43	7.32	3.91	0.44
Currency Exchange Gain (Loss)	-3.96	0.83	-0.76	0.74	0.6
Other Non Operating Income (Expenses)	0.64	0.02	-	-	-
EBT Excluding Unusual Items	47.66	51.55	50.68	45.58	34.32
Pretax Income	47.66	51.55	50.68	45.58	34.32
Income Tax Expense	13.74	15.38	15.04	14.97	13.44
Earnings From Continuing Operations	33.92	36.17	35.64	30.6	20.88
Net Income	33.92	36.17	35.64	30.6	20.88
Net Income to Common	33.92	36.17	35.64	30.6	20.88
Net Income Growth	-6.24%	1.50%	16.44%	46.58%	-15.57%
Shares Outstanding (Basic)	50	50	50	49	49
Shares Outstanding (Diluted)	51	50	51	52	52
Shares Change	0.73%	-1.27%	-1.52%	0.08%	1.26%
EPS (Basic)	0.68	0.72	0.72	0.62	0.42
EPS (Diluted)	0.67	0.72	0.70	0.59	0.40
EPS Growth	-6.96%	2.86%	18.11%	46.65%	-16.74%

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Free Cash Flow	35.31	40.8	31.48	35.88	39.44
Free Cash Flow Per Share	0.70	0.81	0.62	0.69	0.76
Dividend Per Share	0.050	0.050	0.050	0.050	0.040
Dividend Growth	0%	0%	0%	25.00%	60.00%
Gross Margin	83.18%	84.41%	91.23%	90.40%	85.92%
Operating Margin	43.11%	43.43%	55.08%	56.34%	54.09%
Profit Margin	36.07%	38.07%	40.41%	39.08%	31.77%
Free Cash Flow Margin	37.55%	42.94%	35.70%	45.82%	60.01%
EBITDA	41.11	42.06	49.32	44.52	35.97
EBITDA Margin	43.72%	44.26%	55.93%	56.85%	54.74%
D&A For EBITDA	0.58	0.79	0.75	0.4	0.43
EBIT	40.53	41.27	48.57	44.13	35.55
EBIT Margin	43.11%	43.43%	55.08%	56.34%	54.09%
Effective Tax Rate	28.84%	29.83%	29.68%	32.85%	39.17%
Revenue as Reported	-	-	95.31	82.99	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 28, 2026

Data Sources Report a data error